PRMT7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9938332	0.60	4/20
SCHEMBL9938337	0.60	4/20
SCHEMBL6897966	0.83	3/20
SCHEMBL4884765	0.81	3/20
SCHEMBL2829515	0.79	3/20
SCHEMBL2829520	0.79	3/20
SCHEMBL4449190	0.79	3/20
SCHEMBL5055181	0.75	3/20
SCHEMBL5055190	0.75	3/20
SCHEMBL5267666	0.75	3/20
SCHEMBL2040695	0.70	3/20
SCHEMBL6907668	0.70	3/20
SCHEMBL6907691	0.70	3/20
SCHEMBL6907707	0.70	3/20
SCHEMBL6907677	0.69	3/20
SCHEMBL5062936	0.64	3/20
SCHEMBL5062957	0.64	3/20
SCHEMBL6904956	0.54	3/20
SCHEMBL6904961	0.54	3/20
SCHEMBL9941044	0.53	3/20

Clinical trials — most relevant to PRMT7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
L-arginine Treatment in Mild Hypertension	PHASE4	UNKNOWN
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)	PHASE3	RECRUITING
L-Arginine in Pre-Eclampsia	PHASE3	COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors	PHASE1/PHASE2	RECRUITING
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)	PHASE2	NOT_YET_RECRUITING
Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial	PHASE2	COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors	PHASE1	RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD	nan	UNKNOWN
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment	nan	UNKNOWN
The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure	nan	ENROLLING_BY_INVITATION
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD	nan	COMPLETED
Study of the Articular Microbiota in Rheumatoid Arthritis.	nan	COMPLETED
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Biocollection in MyeloDysplastic Syndrome (P-MDS)	nan	RECRUITING
DNA Methylation and Perioperative Pain Treatment	nan	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Diabetes	nan	UNKNOWN
Glucagon Like Peptide-1 in Remote Ischemic Conditioning	nan	COMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PRMT7 binder may also engage these)

Protein	Name	Similarity
Q922X9	—	1.000	Q922X9 →
A6QQV6	—	1.000	A6QQV6 →
Q99MI9	—	1.000	Q99MI9 →
A2AV36	—	0.998	A2AV36 →
Q5U4E8	—	0.998	Q5U4E8 →
Q6PCI6	—	0.994	Q6PCI6 →
Q5ZIB9	—	0.989	Q5ZIB9 →
B3DLB3	—	0.984	B3DLB3 →
D9IVE5	—	0.982	D9IVE5 →
Q9R144	—	0.976	Q9R144 →
PRMT9	Protein arginine N-methyltransferase 9	0.975	landscape →
Q6NTR1	—	0.975	Q6NTR1 →
Q3U3W5	—	0.974	Q3U3W5 →
Q7QIL2	—	0.974	Q7QIL2 →
Q16NS8	—	0.973	Q16NS8 →
A5PK19	—	0.973	A5PK19 →
Q865R1	—	0.973	Q865R1 →
Q3UZW7	—	0.973	Q3UZW7 →
P47823	—	0.973	P47823 →
Q7TMC8	—	0.972	Q7TMC8 →
Q3U2U7	—	0.972	Q3U2U7 →
Q7ZYP6	—	0.972	Q7ZYP6 →
Q9W1V1	—	0.971	Q9W1V1 →
B5DG51	—	0.971	B5DG51 →
A2RV18	—	0.971	A2RV18 →
Q2TBP8	—	0.971	Q2TBP8 →
PRMT1	Protein arginine N-methyltransferase 1	0.971	landscape →
B4I8G2	—	0.971	B4I8G2 →
P0C5J1	—	0.971	P0C5J1 →
B4QI55	—	0.971	B4QI55 →